Compare Biogen Inc (BIIB) vs McDonald's Corp (MCD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs McDonald's Corp — how do they compare? Biogen Inc trades at $191.89 (market cap $28.34B), while McDonald's Corp trades at $269.45 (market cap $191.08B). The key difference: McDonald's Corp is far larger — about 6.7× Biogen Inc's market cap, and McDonald's Corp pays a 2.77% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | MCD | |
|---|---|---|
Market Cap | $28.34B | $191.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $341.06 |
52-Week Low | $122.68 | $264.54 |
Enterprise Value | $30.62B | $244.79B |
Volume | — | 2,230,036 |
Dividend Yield | — | 2.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
McDonald's (MCD) trades at $268.94, down 2.06% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed quarterly EPS results, with a miss in Q3 2025 but beats in Q4 2025 and Q1 2026. Revenue grew to $26.89 billion in 2025, with a net income margin of 31.62%. Recent news highlights the launch of the McDonald's NEXT strategy focusing on automation and better food to win back customers.
The outlook remains supported by strong analyst consensus with a $325.50 price target and 59.68% buy ratings, but risks include inflationary pressures on franchisee margins and high long-term debt of $38.42 billion. The stock offers a dividend yield with a recent $1.86 payout, appealing for income-focused investors amid current market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →
